Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas

Differential regulation of TGF-β–induced, ALK-5–mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma

(2014) Katharina Seystahl et al.   NEURO-ONCOLOGY

Hyperplasia of Pericytes Is One of the Main Characteristics of Microvascular Architecture in Malignant Glioma

(2014) Huiqin Sun et al.   PLoS One

Molecular analysis of a recurrent glioblastoma treated with bevacizumab

(2013) Takuya Furuta et al.   Brain Tumor Pathology

Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth

(2013) Lin Cheng et al.   CELL

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma

(2013) C. Lu-Emerson et al.   NEURO-ONCOLOGY

PDGF Receptor β Signaling in Pericytes Following Ischemic Brain Injury

(2012) Koichi Arimura et al.   CURRENT NEUROVASCULAR RESEARCH

Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma

(2012) M. Nagane et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape

(2011) E. di Tomaso et al.   CANCER RESEARCH

Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma

(2011) Yoshihiro Muragaki et al.   JOURNAL OF NEUROSURGERY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Proliferation of vascular smooth muscle cells in glioblastoma multiforme

(2009) Hiroaki Takeuchi et al.   JOURNAL OF NEUROSURGERY